Cannabis and dementia: Weeding out the evidence

brainXchange, Alzheimer Society of Canada and the CCNA proudly present a webinar: "Cannabis and dementia: Weeding out the evidence."

Date: Wednesday November 6, 2019
Time: 11:00 AM - 12:00 PM (Central) 

Register now. Registration is FREE, but space is limited!

About this webinar

There is increasing interest in the use of cannabinoids as a therapeutic intervention in dementia, particularly for agitation. By the end of this presentation you will be aware that:

  • agitation is a common and persistent symptom in those with Alzheimer’s disease
  • current pharmacotherapies have modest efficacy and/or poor safety
  • there is a pharmacologic rationale for use of cannabinoids
  • limited literature has evaluated the efficacy of THC and related compounds for agitation
  • a pilot study of a cannabinoid for agitation has recently been completed.

 

This integrated knowledge exchange webinar is brought to you by brainXchange in partnership with the Alzheimer Society of Canada and the Canadian Consortium of Neurodegeneration in Aging (CCNA).

The presenter

Dr. Krista L. Lanctôt has a PhD in Clinical Pharmacology from the University of Toronto, with additional training in pharmacoepidemiology.  She is currently a Senior Neuroscientist in Geriatric Psychiatry and in the Hurvitz Brain Sciences Program at Sunnybrook Research Institute, and the Head of Neuropsychopharmacology Research.  She is a Full Professor of Psychiatry and Pharmacology/Toxicology at the University of Toronto, Toronto, Ontario, Canada.  


Sign up for our Newsletter